CS277142B6 - Mouse hybridoma IFNA1-48 producing a monoclonal antibody - Google Patents
Mouse hybridoma IFNA1-48 producing a monoclonal antibody Download PDFInfo
- Publication number
- CS277142B6 CS277142B6 CS905554A CS555490A CS277142B6 CS 277142 B6 CS277142 B6 CS 277142B6 CS 905554 A CS905554 A CS 905554A CS 555490 A CS555490 A CS 555490A CS 277142 B6 CS277142 B6 CS 277142B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- human interferon
- interferon alpha
- ifna1
- monoclonal antibody
- mouse hybridoma
- Prior art date
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Příprava novej homogénnej protilátky, ktorá neutralizuje a viaže ludský interferon alfa 1 a nerozlišuje iné subtypy ludského interferonu alfa. Uvedeného účelu sa dosiahne použitím nového myšieho hybridómu IFNA1-48, produkujúceho monoklonálnu protilátku imunoglobulínovej podtriedy Gl voči rekombinantnému ludskému interferonu alfa 1. Myší hybridóm IFNA1-48 sa využívá v imunodiagnostike a pri čistění ludského interferonu alfa 1.Preparation of a novel homogeneous antibody that neutralizes and binds human interferon alpha 1 and does not discriminate between other subtypes of human interferon alpha. The above purpose is achieved by using a novel mouse hybridoma IFNA1-48, producing a monoclonal antibody of the immunoglobulin subclass G1 against recombinant human interferon alpha 1. The mouse hybridoma IFNA1-48 is used in immunodiagnostics and in the purification of human interferon alpha 1.
Description
1 CS 277142 B61 CS 277142 B6
VIN
Vynález sa týká nového myšieho hybridómu IFNA1-48 produkujú-ceho monoklonálnu protilátku, ktorá neutralizuje a viaže ludskýinterferon alfa 1.The present invention relates to a novel mouse hybridoma IFNA1-48 producing a monoclonal antibody that neutralizes and binds human interferon alpha 1.
Protilátky voči ludskému interferonu alfa i sa připravujú voformě antisér alebo monoklonálnych protilátok. Antiséra sa získa-vajú imunizáciou pokusných zvierat purifikovaným antigénom (lud-ským interferonom alfa 1). Takto připravené protilátky sú nestan-dardně a jednotlivé šarže antisér majú rozdielne vázobnéa neutralizačně schopnosti voči ludskému interferonu alfa 1.Antiséra vykazujú aj krížovú reaktivitu s příbuznými subtypmiÍudského interferonu alfa. Přípravu homogénnych protilátoks neutralizačnou a súčasne s vázobnou aktivitou voči ludskémuinterferonu alfa 1 umožňuje iba hybridómová technika přípravymonoklonálnych protilátok. Takéto monoklonálne protilátky umožňu-jú dokaž přítomnosti íudského interferonu alfa i v róznych biolo-gických materiáloch pomocou citlivých neutralizačných a imunoche-mických stanovení. Hybridómy sa získavajú známým spósobom opísa-ným v literatúre [G. Kóhler, C. Milstein: Nátuře, 256 (1975)].Hybridóm IFNA1-48 nebol doteraz připravený.Antibodies to human interferon alpha 1 are prepared in antisera or monoclonal antibodies. Antisera are obtained by immunizing experimental animals with purified antigen (human interferon alpha 1). The antibodies thus prepared are non-standard and individual batches of antisera have different binding and neutralizing capabilities to human interferon alpha 1. The antisera also exhibits cross-reactivity with related human interferon alpha subtypes. Only the hybridoma technique of preparymonoclonal antibodies allows the preparation of homogeneous antibodies by neutralizing and simultaneously binding to human interferon alpha 1. Such monoclonal antibodies allow the presence of human interferon alpha to be detected in various biological materials by sensitive neutralization and immunochemical assays. Hybridomas are obtained in a manner known in the literature [G. Köhler, C. Milstein: Nature, 256 (1975)] The IFNA1-48 hybridoma has not yet been prepared.
Nevýhody konvenčně připravených antisér voči ludskému inter-feronu alfa i v podstatnej miere odstraňuje vynález, ktoréhopodstatou je myší hybridóm IFNA1-48, produkujúci monoklonálnuprotilátku imunoglobulínovej podtriedy G1 voči rekombinantnémuludskému interferonu alfa 1. Hybridóm IFNA1-48 je uložený voVirologickom ústave SAV, Dúbravská cesta, 842 46 Bratislava. Výhodou hybridómu IFNA1-48 je, že produkuje homogénnu proti-látku, ktorá je schopná špecificky neutralizovat a viazat ludskýinterferon alfa 1 a nerozoznáva iné subtypy Íudského interferonualfa. Po rozmražení buňky hybridómu IFNA1-48 pokračujú v produk-ci! protilátky i bez áalšej imunizácie ludským interferonomalfa 1. PříkladThe disadvantages of conventionally prepared antisera to human alpha interferon are substantially eliminated by the invention, which is essentially the murine hybridoma IFNA1-48, producing a monoclonal antibody of the G1 immunoglobulin subclass against recombinant human interferon alpha 1. The IFNA1-48 hybridoma is deposited in the SAS Institute of Virology, Dubravska cesta, 842 46 Bratislava. The advantage of the IFNA1-48 hybridoma is that it produces a homogeneous anti-substance that is able to specifically neutralize and bind human interferon alpha 1 and does not recognize other subtypes of human interferonualpha. After thawing, the IFNA1-48 hybridoma continues to produce! antibodies even without further immunization with human interferon 1. Example
Hybridómy sa získajú fúziou myších myelómových buniek NSOa buniek získaných zo sleziny myší kmeňa BALB/c imunizovanýchrekombinantným ludským interferonom alfa 1 (Ernst Boehringer--Institute fur Arzneimittelforschung, Viedeň). Po fúzii bolvybratý hybridóm IFNA1-48, ktorý produkuje monoklonálnu protilát-ku imunoglobulínovej podtriedy Gl, selektívne neutrálizujúcua viažúcu ludský interferon alfa 1. Hybridóm IFNA1-48 sa pěstujein vitro v kultivačných médiách alebo in vivo v peritoneálnejdutině myší kmeňa BALB/c. Buňky sa zmrazujú a uchovávajú v teku-tom dusíku a po rozmražení pokračujú v produkcii protilátky bezčfalšej imunizácie ludským interferonom alfa 1. Buňky hybridómuIFNA1-48 rastů in vitro ako suspenzná kultúra a produkujú do kul-tivačného média přibližné 1 μg/ml špecifickej protilátky. Kulti-vačným médiom je Dulbeccova modifikácia Eaglovho minimálnehoesenciálneho média [R. Dulbecco, G. Freeman: Virology 8, 396(1959)]. Toto médium je pre kultiváciu hybridómov doplněné inak-tivovaným koňským sérom (ELÁN CLONĚ). Za účelom získania váčšiehomnožstva monoklonálnej protilátky voči ludskému interferonualfa 1 sa buňky IFNA1-48 aplikovali v množstve 5.106 do perito-neálnej dutiny myši BALB/c. Myš sa desat dní před touto apliká-Hybridomas were obtained by fusing murine NSO mouse myeloma cells and spleen cells from BALB / c mice immunized with recombinant human alpha 1 interferon (Ernst Boehringer-Institute fur Arzneimittelforschung, Vienna). After fusion, the IFNA1-48 hybridoma, which produces the monoclonal antibody immunoglobulin G1 subclass, selectively neutralizing human interferon alpha 1, was selected. The IFNA1-48 hybridoma was grown in vitro in culture media or in vivo in the peritoneal cavity of BALB / c mice. Cells are frozen and stored in liquid nitrogen and, after thawing, continue to produce antibody to blunder immunization with human interferon alpha 1. HybridomaIFNA1-48 growth cells in vitro as a suspension culture and produce approximately 1 µg / ml specific antibody to culture medium. The culture medium is Dulbecco's modification of Eagle's minimal essential medium [R. Dulbecco, G. Freeman: Virology 8, 396 (1959)]. This medium is supplemented with inactivated horse serum for the cultivation of hybridomas (ELAN CLONA). In order to obtain a higher amount of monoclonal antibody to human interferon 1, IFNA1-48 cells were applied at 5 x 10 6 to the BALB / c mouse peritoneal cavity. The mouse will be ten days prior to this
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS905554A CS277142B6 (en) | 1990-11-12 | 1990-11-12 | Mouse hybridoma IFNA1-48 producing a monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS905554A CS277142B6 (en) | 1990-11-12 | 1990-11-12 | Mouse hybridoma IFNA1-48 producing a monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS555490A3 CS555490A3 (en) | 1992-05-13 |
| CS277142B6 true CS277142B6 (en) | 1992-11-18 |
Family
ID=5400653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS905554A CS277142B6 (en) | 1990-11-12 | 1990-11-12 | Mouse hybridoma IFNA1-48 producing a monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS277142B6 (en) |
-
1990
- 1990-11-12 CS CS905554A patent/CS277142B6/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS555490A3 (en) | 1992-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5436154A (en) | Monoclonal antibodies against human Tumor Necrosis Factor α | |
| US4699880A (en) | Method of producing monoclonal anti-idiotype antibody | |
| CA1306961C (en) | Production and characterization of hybridoma antibodies directedspecifically against common determinant(s) present among closely related, but distinct proteins | |
| Sheoran et al. | Monoclonal antibodies to subclass-specific antigenic determinants on equine immunoglobulin gamma chains and their characterization | |
| JP7671275B2 (en) | Anti-IL31 antibodies for animals | |
| Keegan et al. | Characterization of new rat anti-mouse IgE monoclonals and their use along with chimeric IgE to further define the site that interacts with FcϵRII and FcϵRI | |
| US5631349A (en) | Chimeric monoclonal antibodies recognizing human interleukin-2-receptor | |
| Seppälä et al. | Mouse Ig coded by VH families S107 or J606 bind to protein A. | |
| WO2021190587A1 (en) | Broad-spectrum microcystin monoclonal antibody and preparation method therefor | |
| Ichikawa et al. | Monoclonal antibodies to choline acetyltransferase of rat brain | |
| RU2420588C2 (en) | MURINE MONOCLONAL ANTIBODIES BOUND WITH ANTIGEN F1 OF Yersinia pestis, METHOD FOR PRODUCING THEREOF WITH USING YEAST, METHOD AND KIT FOR Yersinia pestis DETECTION | |
| CS277142B6 (en) | Mouse hybridoma IFNA1-48 producing a monoclonal antibody | |
| CS276204B6 (en) | Mouse hybridoma IFNA1-118 producing minoclonal antibody binding human interferon alpha 1 | |
| CS276203B6 (en) | Mouse hybridoma IFNA2-N10 producing monoclonal antibody binding human interferon alpha 2 | |
| Morimoto et al. | Method for the preparation of bispecific F (ab′) 2μ fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments | |
| CS276567B6 (en) | Monoclonal antibody producing IFNA2-N7 mouse hybridoma | |
| CS276080B6 (en) | Mouse hybrid HRP 16-1 producing monoclonal antibody immunoglobulin G2a subclass against ehren peroxidase | |
| Chou et al. | Monoclonal and polyclonal antibodies against human ferritin, a nonspecific tumor marker | |
| JP5448424B2 (en) | Reagent for measuring protein containing Fc of human IgG | |
| ICHIMORI et al. | Establishment of hybridomas secreting monoclonal antibodies against Cε2 and Cε4 domains of human IgE | |
| EP0568500A1 (en) | Anti-idiotype monoclonal antibodies directed against anti-TNF antibodies | |
| EP1414859B1 (en) | Anti-ssrp-1 monoclonal antibodies and hybridomas producing said antibodies | |
| JPWO2019152810A5 (en) | ||
| MARCHAND et al. | Production and partial characterization of monoclonal antibodies against 3, 3′, 5-triiodo-l-thyronine | |
| CS272889B1 (en) | Mouse lymphocyte hybridome blv p 24 ueo-25 e 11/8 |